|
1
|
Joensuu H, Hohenberger P and Corless CL:
Gastrointestinal stromal tumour. Lancet. 382:973–983. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Killian JK, Kim SY, Miettinen M, Smith C,
Merino M, Tsokos M, Quezado M, Smith WI Jr, Jahromi MS, Xekouki P,
et al: Succinate dehydrogenase mutation underlies global epigenomic
divergence in gastrointestinal stromal tumor. Cancer Discov.
3:648–657. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Isosaka M, Niinuma T, Nojima M, Kai M,
Yamamoto E, Maruyama R, Nobuoka T, Nishida T, Kanda T, Taguchi T,
et al: A Screen for epigenetically silenced microRNA genes in
gastrointestinal stromal tumors. PLoS One. 10:e01337542015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niinuma T, Suzuki H, Nojima M, Nosho K,
Yamamoto H, Takamaru H, Yamamoto E, Maruyama R, Nobuoka T, Miyazaki
Y, et al: Upregulation of miR-196a and HOTAIR drive malignant
character in gastrointestinal stromal tumors. Cancer Res.
72:1126–1136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Valastyan S and Weinberg RA: Tumor
metastasis: Molecular insights and evolving paradigms. Cell.
147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo
YY: MicroRNA-21 targets tumor suppressor genes in invasion and
metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fletcher CD, Berman JJ, Corless C,
Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti
H, Rubin BP, et al: Diagnosis of gastrointestinal stromal tumors: A
consensus approach. Hum Pathol. 33:459–465. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Taguchi T, Sonobe H, Toyonaga S, Yamasaki
I, Shuin T, Takano A, Araki K, Akimaru K and Yuri K: Conventional
and molecular cytogenetic characterization of a new human cell
line, GIST-T1, established from gastrointestinal stromal tumor. Lab
Invest. 82:663–665. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C (T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html
|
|
16
|
Cai J, Wu J, Zhang H, Fang L, Huang Y,
Yang Y, Zhu X, Li R and Li M: miR-186 downregulation correlates
with poor survival in lung adenocarcinoma, where it interferes with
cell-cycle regulation. Cancer Res. 73:756–766. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He W, Feng J, Zhang Y, Wang Y, Zang W and
Zhao G: microRNA-186 inhibits cell proliferation and induces
apoptosis in human esophageal squamous cell carcinoma by targeting
SKP2. Lab Invest. 96:317–324. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ruan T, He X, Yu J and Hang Z:
MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo
signaling and tumorigenesis in hepatocellular carcinoma. Oncol
Lett. 11:2941–2945. 2016.PubMed/NCBI
|
|
19
|
Yao K, He L, Gan Y, Zeng Q, Dai Y and Tan
J: MiR-186 suppresses the growth and metastasis of bladder cancer
by targeting NSBP1. Diagn Pathol. 10:1462015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li H, Yin C, Zhang B, Sun Y, Shi L, Liu N,
Liang S, Lu S, Liu Y, Zhang J, et al: PTTG1 promotes migration and
invasion of human non-small cell lung cancer cells and is modulated
by miR-186. Carcinogenesis. 34:2145–2155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cui G, Cui M, Li Y, Liang Y, Li W, Guo H
and Zhao S: MiR-186 targets ROCK1 to suppress the growth and
metastasis of NSCLC cells. Tumour Biol. 35:8933–8937. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu X, Shen H, Yin X, Long L, Xie C, Liu
Y, Hui L, Lin X, Fang Y, Cao Y, et al: miR-186 regulation of Twist1
and ovarian cancer sensitivity to cisplatin. Oncogene. 35:323–332.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang ZL, Bai ZH, Wang XB, Bai L, Miao F
and Pei HH: miR-186 and 326 predict the prognosis of pancreatic
ductal adenocarcinoma and affect the proliferation and migration of
cancer cells. PLoS One. 10:e01188142015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Baxter RC: IGF binding proteins in cancer:
Mechanistic and clinical insights. Nat Rev Cancer. 14:329–341.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yen YC, Hsiao JR, Jiang SS, Chang JS, Wang
SH, Shen YY, Chen CH, Chang IS, Chang JY and Chen YW: Insulin-like
growth factor-independent insulin-like growth factor binding
protein 3 promotes cell migration and lymph node metastasis of oral
squamous cell carcinoma cells by requirement of integrin b1.
Oncotarget. 6:41837–41855. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Georges RB, Adwan H, Hamdi H, Hielscher T,
Linnemann U and Berger MR: The insulin-like growth factor binding
proteins 3 and 7 are associated with colorectal cancer and liver
metastasis. Cancer Biol Ther. 12:69–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hansel DE, Rahman A, House M, Ashfaq R,
Berg K, Yeo CJ and Maitra A: Met proto-oncogene and insulin-like
growth factor binding protein 3 overexpression correlates with
metastatic ability in well-differentiated pancreatic endocrine
neoplasms. Clin Cancer Res. 10:6152–6158. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Braconi C, Bracci R, Bearzi I, Bianchi F,
Sabato S, Mandolesi A, Belvederesi L, Cascinu S, Valeri N and
Cellerino R: Insulin-like growth factor (IGF) 1 and 2 help to
predict disease outcome in GIST patients. Ann Oncol. 19:1293–1298.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dupart JJ, Trent JC, Lee HY, Hess KR,
Godwin AK, Taguchi T and Zhang W: Insulin-like growth factor
binding protein-3 has dual effects on gastrointestinal stromal
tumor cell viability and sensitivity to the anti-tumor effects of
imatinib mesylate in vitro. Mol Cancer. 8:992009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen QY, Jiao DM, Wu YQ, Chen J, Wang J,
Tang XL, Mou H, Hu HZ, Song J, Yan J, et al: MiR-206 inhibits
HGF-induced epithelial-mesenchymal transition and angiogenesis in
non-small cell lung cancer via c-Met/PI3k/Akt/mTOR pathway.
Oncotarget. 7:18247–18261. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang N, Wu Z, Lin L, Zhou M, Wang L, Ma
H, Xia J, Bin J, Liao Y and Liao W: MiR-338-3p inhibits
epithelial-mesenchymal transition in gastric cancer cells by
targeting ZEB2 and MACC1/Met/Akt signaling. Oncotarget.
6:15222–15234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ohta K, Hoshino H, Wang J, Ono S, Iida Y,
Hata K, Huang SK, Colquhoun S and Hoon DS: MicroRNA-93 activates
c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by
directly inhibiting PTEN and CDKN1A. Oncotarget. 6:3211–3224. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo F, Wang Y, Liu J, Mok SC, Xue F and
Zhang W: CXCL12/CXCR4: A symbiotic bridge linking cancer cells and
their stromal neighbors in oncogenic communication networks.
Oncogene. 35:816–826. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rhodes LV, Short SP, Neel NF, Salvo VA,
Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, et al: Cytokine
receptor CXCR4 mediates estrogen-independent tumorigenesis,
metastasis, and resistance to endocrine therapy in human breast
cancer. Cancer Res. 71:603–613. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ottaiano A, Franco R, Talamanca Aiello A,
Liguori G, Tatangelo F, Delrio P, Nasti G, Barletta E, Facchini G,
Daniele B, et al: Overexpression of both CXC chemokine receptor 4
and vascular endothelial growth factor proteins predicts early
distant relapse in stage II–III colorectal cancer patients. Clin
Cancer Res. 12:2795–2803. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Katayama A, Ogino T, Bandoh N, Nonaka S
and Harabuchi Y: Expression of CXCR4 and its down-regulation by
IFN-gamma in head and neck squamous cell carcinoma. Clin Cancer
Res. 11:2937–2946. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang HC, Li TY, Chao YJ, Hou YC, Hsueh YS,
Hsu KH and Shan YS: KIT exon 11 codons 557–558 deletion mutation
promotes liver metastasis through the CXCL12/CXCR4 axis in
gastrointestinal stromal tumors. Clin Cancer Res. 22:3477–3487.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen J, Wei D, Zhao Y, Liu X and Zhang J:
Overexpression of EFEMP1 correlates with tumor progression and poor
prognosis in human ovarian carcinoma. PLoS One. 8:e787832013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Z, Cao CJ, Huang LL, Ke ZF, Luo CJ,
Lin ZW, Wang F, Zhang YQ and Wang LT: EFEMP1 promotes the migration
and invasion of osteosarcoma via MMP-2 with induction by AEG-1 via
NF-κB signaling pathway. Oncotarget. 6:14191–14208. 2015.
View Article : Google Scholar : PubMed/NCBI
|
